Clemmons Publications

  Recent Publications
Sakai K, Clemmons DR. Glucosamine induces resistant to insulin-like growth factor (IGF- I) and insulin in Hep G-2 cell cultures:Biological significance of IGF-I/insulin hybrid receptors, Endocrinology 144: 2388-2395, 2003.

Moralez A, Busby WH Jr, Clemmons DR. Control of insulin-like growth factor binding protein-5 protein synthesis and secretion by human fibroblasts and porcine aortic smooth muscle cells. Endocrinology 144: 2489-2495, 2003.

Ling Y, Maile LA, Clemmons DR. Tyrosine phosphorylation of the 3 subunit of the V 3 integrin is required for the membrane association of tyrosine phosphatase SHP-2 and its subsequent transfer to insulin-like growth factor-I receptor . Mol Endocrinol, 17:1824-1833, 2003.

Maile LA, Clarke JB, Clemmons DR. The association between integrin associated protein and SHPS-1 regulates IGF-I receptor signaling in vascular smooth muscle cells. Mol Biol Cell, 14:3519-28, 2003.

Hsieh T, Gordon RE, Clemmons DR, Busby WH Jr, Duan C. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF binding proteins. J Biol Chem, 278:42886-42892, 2003.

Maile LA and Clemmons DR: The integrin associated protein binding domain of thrombospondin-1 enhances IGF-I receptor signaling in vascular smooth muscle cells. Circ Res, 93: 925-931, 2003.

Clemmons DR: The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27, 2004.

Rosen CJ, Bitnell-Ackert CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Bramer WG, Sipos J, Clemmons DR, NelsonT, Bouxsein ML, Horowitz M: Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density and an altered osteoblast differentiation program. Bone, 35:1046-1058, 2004.

Gjustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons DR, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247, 2004.

Clemmons DR, Strasburger C. Monitoring the response to treatment in acromegaly. J Clin Endocrinol Metab 89:5289-5291, 2004.

Hou J, Clemmons DR, Smeekens S: Expression and characterization of a serine protease that preferentially cleaves insulin-like growth factor binding protein-5. J Cell Biochem, 94:470-484, 2005.

Clemmons DR, Maile LA. Interaction between IGF-I receptor and alpha V beta 3 integrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol Endocrinol, 19:1-11, 2005.

Moralez AM, Maile LA, Clarke J, Busby WH Jr, Clemmons DR: Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions. J Cell Physiol, epub Feb 7, 2005.

Ling Y, Maile LA, Badley-Clarke J, Clemmons DR: DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem, 280:3151-3158, 2005.

Ling Y, Maile LA, Leiskovska J, Badley-Clarke J, Clemmons DR: Role of SHPS-1 in the regulation of insulin-like growth factor-I (IGF-I) Stimulated Shc and MAP kinase activation in vascular smooth muscle cells. Mol Biol Cell, 16:3353-3360, 2005.

Clemmons DR, Moses AC, Sommer A, Jaccon W, Rogol AD: Rh/IGF-I/IGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274, 2005.

Barken AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691, 2005.

Clemmons DR, Sleevi M, Busby WH Jr. Recombinant, nonglycosylated human insulin-like growth factor binding protein-3 (IGFBP-3) is degraded preferentially after administration of type II diabetics, resulting in increased and endogenous glycosylated IGFBP-3. J Clin Metab 90:6561-6568, 2005.

Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clark J, Clemmons DR. IGF-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the beta 3 subunit of the alpha V beta 3. Mol Endocrinol 20:405-413, 2005.

Ruan W, Fahlbusch F, Clemmons Dr, Monaco ME, Walden PD, Silva A, Schmid H, Kleinberg DL. SOM230 Inhibits IGF-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype preceptor 3? Mol Endocrinol 20:426-436, 2006.

Kwon M, Ling Y, Maile LA, Badley-Clark J, Clemmons DR. Recruitment of the tyrosine phosphatase SHP-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor I dependent PI-3 kinase activation in smooth muscle cells. Endocrinol 147:1458-1465, 2006.

Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clark J, Ling Y, Clemmons DR. The heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol 20:881-892, 2006.

Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons DR, Yakar S, Leroith D Recombinant human insulin-like growth factor-I (rhIGF-I) treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellius (DM). Endocrinol 147:2619-30, 2006.

Lievskovska J, Ling Y, Clark JB, Clemmons DR The role of Src kinase in insulin-like growth factor dependent mitogenic signaling in vascular smooth muscle cells. J Biol Chem. 281:25041-53, 2006.

Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinol, 148:2435-43, 2007.

Clemmons DR, Sleevi M, Allan G, Sommer A Effects of combined recombinant IGF-I and IGFBP-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J Clin Endocrinol Metab 92:, 2652, 2658- 2007.

Miller EC, Capps BE, Sanghani RR, Clemmons DR, Maile LA: Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Invest Ophthalmol Vis Sci 48:3878-3887, 2007

Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR. Protease resistant IGFBP-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinol, 148:5002-5010, 2007.

Xi G, Maile LA, Yoo SE, Clemmons DR. Expression of the human beta3 integrin subunit in mouse smooth muscle cell enhances IGF-I stimulated signaling and proliferation. J Cell Physiol, 214:306-315, 2008.

Demambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. Gender specific changes in bone turnover and skeletal architecture in IGFBP-2-null mice. Endocrinol:149:2051-2061, 2008.

Maile LA, Capps BE, Miller EC, Allen LB, Veluvolu U, Aday A, Clemmons DR. Glucose regulation of integrin associated protein cleavage controls the response of vascular smooth muscle cells to insulin like growth factor-I. Mol Endocrinol 22:1226-1237, 2008.

Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR. Insulin like growth factor-I stimulates Shc dependent PI-3 kinase activation via Grb-2 associated p85 in vascular smooth muscle cels. J Biol Chem 283:16320-16331, 2008.

Xi G, Shen X, Clemmons DR. p66Shc negatively regulates IGF-I signaling transduction via inhibition of p52shc binding to SHPS-1 leading to impaired Grb2 membrane recruitment. Mol Endocrinol 22:2162-2175, 2008.

Maile LA, Aday AW, Busby WH, Sanghani R, Veluvolu U, Clemmons DR. Modulation of integrin-antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin. J Cell Biochem 105:437-446, 2008.

Maile LA, Capps BE, Miller EC, Aday AW, Clemmons DR. IAP association with SHPS-1 regulates IGF-I signaling in vivo. Diabetes 57:2637-2643, 2008.

Jimenez C, Burman P, Abs R, Clemmons D, Drake W, Hutson K, Messig M, Thorner M, Trainer P, Gagel R. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159:517-23, 2008

Busby WH Jr, Yocum SA, Rowland M, Kellner D, Lazerwith S, Sverdrup F, Yates M, Radabaugh M, Clemmons DR. Complement 1s is the serine protease that cleaves IGFBP-5 in human osteoarthritic joint fluid. Osteroarthritis Cart 17:547-555, 2009.

Webb SM, Strasburger CJ, Mo D, Hartman ML. Melmed S, Jung H, Blum SF, Attanasio AF; HypoCCS International Advisory Board. J Clin Endocrinol Metab 94:392-399, 2009

Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, Leroith D: Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J 23:709-19, 2009

Allen LB, Capps BE, Miller EC, Clemmons DR, Maile LA. Glucose oxidized low-density lipoproteins enhance IGF-I stimulated smooth muscle cells proliferation by inhibiting integrin associated protein cleavage. Endocrinol 150:1312-19, 2009

Shen X, Xi G, Clemmons DR. Identification of novel SHPS-1 association protein and their roles in the regulation of insulin-like growth factor-dependent responses in vascular smooth muscle cells. Mol Cell Proteomics, epub March 18, 2009
Curriculum Vitae